Cortagen Peptide 20mg

Description

What Is Cortagen Peptide?

Cortagen peptide is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Pro (AEDP), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Cortagen targets central nervous system (CNS) tissue, functioning as a CNS bioregulator that modulates gene expression in cerebral cortex neurons, glial cells, and supporting neural tissue. It belongs to the Khavinson bioregulator peptides class — short regulatory peptides that exhibit tissue-specific gene expression modulation at physiological concentrations — and has been studied in preclinical models of age-related cognitive decline, nerve damage, and neuroprotection.

Among the Khavinson bioregulator peptides, cortagen addresses one of the most critical and difficult-to-target organ systems: the aging brain. The blood-brain barrier severely limits the delivery of conventional neuroprotective compounds to CNS tissue. Short bioregulator peptides like cortagen offer a research advantage due to their low molecular weight and capacity to cross biological barriers more readily than large-molecule therapeutics. PrymaLab Cortagen 20mg is manufactured to high purity standards and supplied exclusively for qualified preclinical research.

Cortagen 20mg: Key Specifications

How Cortagen Works: Bioregulator Mechanism of Action

Cortagen operates through the Khavinson epigenetic bioregulation mechanism — direct interaction with complementary DNA sequences in the promoter regions of CNS-specific genes governing neuronal survival, synaptic plasticity, neurotransmitter synthesis, and glial cell support functions.

Neuronal Gene Expression Modulation

Research from the Khavinson group demonstrates that cortagen modulates the expression of genes critical to neuronal function, including genes encoding brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), synaptic vesicle proteins, and neurotransmitter synthetic enzymes. In aged brain tissue models, cortagen administration was associated with restoration of neuronal gene expression profiles toward patterns characteristic of younger, functionally competent neural tissue. This gene-level normalization mechanism is distinct from conventional nootropic compounds that modulate receptor activity or neurotransmitter reuptake.

Neuroprotection and Neuronal Survival

Cortagen has been studied for its effects on neuronal survival pathways, including anti-apoptotic gene expression (Bcl-2 family), antioxidant defense enzyme expression (superoxide dismutase, catalase, glutathione peroxidase), and mitochondrial function genes in neural tissue. These neuroprotective gene expression effects are particularly relevant in models of age-related neurodegeneration, where oxidative stress and mitochondrial dysfunction drive progressive neuronal loss.

Glial Cell Support and Neuroinflammation

Beyond direct neuronal effects, cortagen research includes its modulation of glial cell gene expression — particularly astrocyte and microglial activation patterns that contribute to neuroinflammation in aging brain tissue. Chronic low-grade neuroinflammation (neuro-inflammaging) driven by over-activated microglia is a major contributor to age-related cognitive decline and neurodegenerative pathology. Cortagen’s modulation of microglial activation gene expression represents a bioregulatory approach to this central aging mechanism.

Cortagen Peptide Benefits: What Research Shows

The following reflects published preclinical and gerontological literature. PrymaLab Cortagen 20mg is supplied exclusively for research purposes.

Cognitive Function in Aging Models

Published research from the Khavinson program reports that cortagen administration in aged animal models was associated with improved cognitive function indices, including enhanced performance on spatial memory tasks (Morris water maze), improved associative learning, and preserved working memory capacity compared to untreated age-matched controls. These cognitive improvements correlated with restored neuronal gene expression profiles in hippocampal and cortical tissue.

Nerve Damage and Repair Models

Cortagen peptide benefits have been studied in experimental nerve damage models, including peripheral nerve injury, spinal cord compression, and excitotoxic neuronal damage paradigms. Preclinical data indicates enhanced neuronal survival, improved axonal regeneration markers, and accelerated functional recovery in cortagen-treated animals. These findings position cortagen as a research compound of interest in neurological repair models where gene expression normalization may support endogenous repair mechanisms.

Anti-aging Neuroprotection

In gerontological models, cortagen has been studied alongside other Khavinson bioregulators for its contribution to multi-system anti-aging protocols. Published data from longitudinal animal studies indicates that cortagen-treated cohorts maintained neurological function parameters at ages where untreated controls showed significant cognitive and motor decline, supporting the bioregulation hypothesis that short peptides can modulate the rate of CNS aging.

Cortagen vs. Vesilute: Neuroprotective Bioregulator Comparison

How to Store and Handle PrymaLab Cortagen 20mg

1. Store lyophilized at −20°C. Keep sealed, desiccated, and protected from light. Stable for 24+ months.
2. Allow vial to reach room temperature before opening to prevent condensation.
3. Reconstitute with appropriate sterile solvent. Add slowly along vial wall.
4. Use reconstituted solution within 2–4 weeks. Refrigerate at 2–8°C.
5. Avoid repeated freeze-thaw cycles. Aliquot into single-use portions.
6. Retain the Certificate of Analysis for lot traceability.

Why Choose PrymaLab Cortagen 20mg?

PrymaLab supplies Cortagen 20mg as a high-purity research-grade bioregulator peptide verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each batch ships with a unique lot number and Certificate of Analysis. Independent third-party testing ensures unbiased quality verification and full traceability for GLP-compliant research.

Frequently Asked Questions About Cortagen Peptide

What is cortagen peptide and what does it target?

Cortagen is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Pro, AEDP) developed by Professor Khavinson targeting the central nervous system. It modulates gene expression in cerebral cortex neurons, glial cells, and supporting neural tissue. Research applications include cognitive aging, nerve damage repair, and neuroprotection in preclinical gerontology models.

What are the reported cortagen peptide benefits?

Published research reports cortagen peptide benefits including improved cognitive function in aged animal models (spatial memory, associative learning), enhanced neuronal survival in nerve damage paradigms, restored neurotrophic factor expression (BDNF, NGF), reduced neuroinflammatory markers, and maintained neurological function in longitudinal aging studies. All reported benefits are from preclinical research.

How does cortagen differ from other neuroprotective compounds?

Cortagen operates through epigenetic gene expression modulation rather than receptor agonism or neurotransmitter reuptake modification. This means it targets the transcriptional programs governing neuronal function rather than acutely modulating synaptic signaling. Among Khavinson bioregulators, cortagen provides direct neuronal effects complementary to vesilute’s indirect cerebrovascular neuroprotection.

How should cortagen be stored?

Store lyophilized cortagen at −20°C, desiccated and protected from light, for 24+ months stability. After reconstitution, store at 2–8°C and use within 2–4 weeks. Aliquot to avoid freeze-thaw cycles.

What testing standards apply?

PrymaLab Cortagen 20mg is verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Independent third-party testing with batch-specific Certificate of Analysis ensures quality and traceability.

Research Disclaimer

For Research Use Only. PrymaLab Cortagen 20mg is intended exclusively for qualified preclinical research use. This product is not intended for human consumption, therapeutic use, veterinary treatment, or any application outside controlled research environments. Cortagen has not been approved by the FDA or any equivalent regulatory authority for therapeutic use. All research applications described are from published preclinical and gerontological literature. Researchers are responsible for regulatory compliance.